Antiretroviral Treatment Strategies in Relation to Adherence, Resistance and Virological Treatment Failure
Antiretroviral Treatment Strategies in Relation to Adherence, Resistance and Virological Treatment Failure
This project aims to assess different antiretroviral treatment strategies, optimally
 controlled and conventional, in relation to drug resistance and virological treatment
 failure. A Randomised Controlled trial (RCT) where Vietnamese HIV+ patients with CD4+ T-cells
 <200/ul are randomized into either enhanced treatment support (ETS) through peer supporters
 or The National AIDS Control Program recommended self supervised treatment (SST). The
 treatment strategies will be assessed and compared in relation to treatment adherence and
 drug resistance development with virological treatment failure as primary endpoint. The
 results from this project will lead to an increased knowledge in relation the impact of
 treatment support on adherence, virological suppression and resistance development and have
 an impact on HIV treatment policies in low income settings globally.
Aim To study the impact of patient support on selective drug pressure, defined by
 semi-quantitative assessments of adherence, on the viral suppression and resistance
 development through a randomised controlled trial of HIV positive patients randomised in
 enhanced treatment support (ETS) and self supervised treatment (SST).

 Specific Objectives

 1. To create a study population 600 HIV+ patients with CD4+ T-cell count of <200/ul and
 randomize in two different treatment cohorts, enhanced treatment support (ETS) and
 conventional self-supervised treatment (SST).

 2. To monitor the patients using semi-quantitative assessments of adherence, clinical
 status including clinical examinations (every 3 months), viral load and CD4+ T-cell
 count (every 6 months) during 24 months with virological treatment failure as primary
 endpoint.

 3. To compare the ETS and SST cohorts with respect to the primary endpoint, virological
 treatment failure, in relation to the semi-quantitative assessments of adherence and to
 analyse the mechanism of selective drug pressure for the development of resistance
 including resistance in minor viral subpopulations.

 4. To conduct a cost effectiveness assessment comparing ETS and SST with respect to the
 labour and infrastructural cost, virological treatment failure and change to second line
 therapy.

 The study is conducted in Quang Ninh Province, the area hardest hit by the HIV epidemic in
 Vietnam with a known HIV+ prevalence above 1%. A study population of 600 HIV+ patients with
 CD4+ T-cell count of <200 are being be recruited in four districts, Ha Long, Uong Bi, Yen
 Huong and Dong Trieu. Each HIV+ person is examined according to WHO guidelines. HIV+ persons
 receive a complete physical examination, clinical staging of HIV infection, opportunistic
 infections including HBV, HCV and tuberculosis. Laboratory testing will include Full blood
 count, CD4+ T-cell count, viral load using the affordable and simple ELISA based ExaVirR
 viral load test (http://www.cavidi.se), liver enzymes, PAP smear and pregnancy test for
 women. If indicated (e.g. prolonged cough) chest X-ray, sputum microscopy for AFB are done.

 Opportunistic infections in HIV+ patients are treated according to national guidelines. HIV+
 persons receive counselling including information about the disease and the plan for care and
 treatment, follow-up visits, nutrition and living, prevention of HIV transmission including
 safe sex, harm reduction measures, the use of birth control methods and prevention of mother
 to child HIV transmission.

 Inclusion and exclusion criteria's are described below. The patients will be randomised into
 two equally large cohorts, receiving either of two different treatment strategies a) enhanced
 treatment support (ETS) (described below) and Self-supervised treatment (SST). Co-infections
 are assessed, diagnosed and the treatment adjusted according to the national guidelines for
 such situations. The patients are studied with respect to: (i) virological treatment failure,
 (ii) adverse effects. (iii) patient's adherence to treatment strategy. First drug regimen for
 all patients including stavudine, lamivudine, nevirapine or efavirenz dosages, follow up for
 adverse effects and regimen alteration are done according to national guidelines. The health
 care workers are trained in regular monitoring of patients and implementation of optimal
 treatment strategy. All procedures and treatment will follow the national guidelines. Follow
 up consultations including physical examinations and tests are done every 3 month.

 The tests will include full blood count, CRP, electrolytes, liver enzymes as well as other
 indicated. Viral load are monitored every 6 month and CD4+ T-cell count every 12 month.

 The number of patients needed for each arm of the experiment was estimated assuming a
 difference between arms of 15 percent units for treatment failure and corresponding baseline
 percentage of 20%. Requiring a power of 80% and a significance level of 5% the necessary
 number is about 300 per arm. Inflating the size by 30% to compensate for expected loss to
 follow up the investigators get just under 300 patients per arm. The assumptions about
 differences are based on the following: a) Differences larger than 10% units in virological
 treatment failure are indications for review and modification of treatment strategies; b)
 group differences in virological treatment failure less the 20% are unlikely to lead to
 policy changes in Vietnam. The discussion above uses a binary variable like failure/no
 failure. Performing analysis on quantitative variables like CD4 T-cell readings, which are
 more informative, will in some cases have considerably higher power than the corresponding
 binary.

 In the ETS strategy an "internal supporter", family member or other person trusted by the
 patient, is trained to fill in a checklist whether the drugs has been taken and if this was
 observed. An"external supporter" - a peer selected PLWHA visit the patient twice weekly the
 first two months. The external supporter follows a checklist and ask about general well
 being, psychological problems or adverse drugs reactions as well as go through the adherence
 since last visit, using the internal supporter checklist. If the adherence is good, the
 number of visits are decreased to once weekly after two months, if not, the number of visits
 are intensified. If there are any symptoms of opportunistic infections, immunological
 reconstruction syndrome or adverse drug reactions the patient are refered for medical
 checkup.. In SST the patient will self be responsible to take the drugs. At initiation
 treatment counseling are provided. In both groups the drugs are provided in a pre-packed
 dosage form for easy remembering and counting of the pills.

 The patients are followed for 24 months and monitored through clinical examination (each 3
 months), viral load in plasma (each six months), CD4- T-cell counts (each 6 months) and
 assessment of well-being (every 3 months). Adherence among patients are assessed using
 Contextualised Adult AIDS Clinical Trials Group (AACTG) Adherence Instruments (Chesney et al,
 2000). AACTG Adherence Instruments consists of two questionnaires and the first questionnaire
 is specifically developed to be used for baseline assessment of adherence. The second
 questionnaire version is developed for assessment of adherence during follow-up visits.
 Adherence are assessed using the AACTG Adherence Instruments every third month in both the
 ETS and SST groups. One person is present at the clinic to answer questions regarding the
 questionnaire and provide help if necessary. Adherence is also measured by pill count
 conducted by the External supporters, enabling calculation of the proportion of drugs
 remaining out of the total amount of prescribed drugs. Assessment of side effects according
 to WHO suggested monitoring and management of ARV drugs are done together with the clinical
 examination each three months.

 The primary endpoint is virological treatment failure defined as a viral load of 1 fg reverse
 transcriptase activity/ml, corresponding to 200 copies/ml, at 1 year and 2 years after
 starting treatment. Drug Resistance is determined using a selective real-time PCR for the
 detection of the critical mutations in the RT-gene, as a marker for whether virological
 treatment failure that occurs with wild-type virus or resistant virus. The secondary
 endpoints immunological treatment failure (no rise in CD4+ T-cell count at 1 year) and
 clinical treatment failure as defined by a new AIDS defining illness or death due to HIV/AIDS
 (including TB and opportunistic infection) after starting treatment.

 Costing of the two different strategies will be carried out by collecting monetary data of
 expenses of drugs, test, allowance and other expenses from perspective of the HIV/AIDS
 treatment provider during ART. The investigators follow the basic principles of
 activity-based costing by identifying all activities necessary to provide the EST and SST and
 then calculate the costs of carrying out each activity. Costs for each activity comprise
 recurrent and capital costs, direct and indirect costs. Recurrent costs are the routine costs
 of resources that are consumed within a year, i.e., non-capital items such as labor and
 medical supplies. Capital costs represent the annual portion of the cost of durable HIV Sida
 DOTARV assets. Effectiveness will be measured by percentages of patients with virological
 treatment failure defined as Viral Load>400 copies/ml.

 The statistical analysis mainly consists in the comparison between the two groups with
 respect to the defined primary endpoint, virological treatment failure, and possibly the
 secondary endpoints immunological treatment failure and clinical treatment failure, in
 relation to the semi-quantitative assessments of adherence. Basically standard statistical
 methods will be used. Regression models with outcome as the dependent variable and a group
 indicator together with person characteristics as independent variables will be the main
 approach. For binary outcomes, logistic regression will be used. Attention has to be paid to
 the particular, often skewed, distributions of variables like CD4+ T-cell counts and viral
 load. Transformations or the use of non-parametric approaches are likely to be necessary if
 such measures are not dichotomised and used in linear regression. The correlation between
 drug resistance to the used drugs (stavudine, lamivudine, nevirapine) and adherence will be
 statistically analysed in order to study whether the basic mechanisms of selective drug
 pressure result in a concave or bell-shaped resistance - adherence relationship, for these
 drugs during ETS or SST in a low-income setting.

 The investigators will strictly comply with widely recognized international texts and codes
 of practice including the Helsinki agreement. In this project one patient cohort will receive
 ETS and the other SST. Both the OTC and SST cohorts will be encouraged to proceed regularly
 with their drug treatment and to present difficulties that they may encounter in doing so.
 For the project period, the project will meet the costs of ARV for the cohorts. Patients'
 biological samples are collected and used only after written consent. All specimens are coded
 to protect the identity of patients and to ensure confidentiality. Patients are recruited in
 a consecutive manner without regard to race or other exclusion considerations.
 Confidentiality is assured by using codes for patient identification, and confidentially laws
 will be strictly observed when processing human clinical information. No patient identifying
 information will be published or available after the requisite clinical data have been
 collected, and consent will be obtained for the use of all data and tissues. Data is
 accessible only to members and coordinators of the tissue procurement facility and research
 team, under approved guidelines.
Inclusion Criteria:

 -  WHO stage IV of HIV disease, regardless of the CD4 count

 -  WHO stage III of HIV disease with a CD4 count < 350/mm3

 -  WHO stages I or II with a CD4 count < 200/mm3

 Exclusion Criteria:

 -  Pregnancy

 -  Ongoing severe opportunistic infections

 -  Institutionalized patients.